Riskpilot← Back to searchSign inGet full accessPROPHY Med AB
ABDissolvedOrg 5566405626Research and experimental development on natural sciences and engineering · NACE 7210Est. 20030 employees
Revenue 2024
SEK 0
EBITDA margin
—
-25% vs 2023
Equity ratio
85.5%
Financial strength
Net profit 2024
SEK -5K
-25% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -5K | -25% |
| Net profit | SEK -5K | -25% |
| Total assets | SEK 117K | +0% |
| Equity | SEK 100K | +0% |
| Employees | 0 | — |
Legal name
PROPHY Med AB
Org number
5566405626
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17 februari 2003
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Styrelsen ska bestå av 5 styrelseledamöter och 0 styrelsesuppleanter.
Company purpose
Bolaget skall bedriva forskning, utveckling av metoder, läkemedel och medicinsk utrustning, allt inom medicin och medicinsk teknik samt äga och förvalta fast och lös egendom ävensom idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −124 | −333 | −213 | −226 | −215 | −22 | −18 | −21 | −4 | −5 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −124 | −333 | −213 | −226 | −215 | −22 | −18 | −21 | −4 | −5 |
| Net financials | — | — | −1 | — | — | — | — | — | — | — |
| Profit before tax | −124 | −333 | −214 | −226 | −215 | −22 | −18 | −21 | −4 | −5 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −124 | −333 | −214 | −226 | −215 | −22 | −18 | −21 | −4 | −5 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 223 | 216 | 115 | 103 | 147 | 115 | 117 | 116 | 117 | 117 |
| Equity | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 123 | 116 | 15 | 3 | 47 | 15 | 17 | 16 | 17 | 17 |
| Total debt | 123 | 116 | 15 | 3 | 47 | 15 | 17 | 16 | 17 | 17 |
EBITDA margin
-500000.0%
This company
15.8%
Market median
-3164657% vs market
20152024
Equity ratio
85.5%
This company
38.2%
Market median
+124% vs market
20152024
Return on equity
-5.0%
This company
18.4%
Market median
-127% vs market
20152024
Net profit margin
-500000.0%
This company
8.1%
Market median
-6172940% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM Auditor Substitute | Auditor Substitute | 2022 | — | — |
AO Audit | Audit | 2025 | — | — |
EK | Audit | 2021 | — | — |
FO | Audit | 2022 | — | — |
AD Auditor Substitute | Auditor Substitute | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Tikomed AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Tikomed AB
PROPHY Med AB Board members of PROPHY Med AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jonatan Mattias Hansson | Auditor Substitute | 0 companies |
| Anders Olof Persson | Audit | 0 companies |
| Eva Katarina Ljungqvist | Audit | 0 companies |
| Fredrik Oskar Norrman | Audit | 0 companies |
| Anders Daniel Johansson | Auditor Substitute | 0 companies |
| Johan Adam Patrik Bruce | Chairman | 0 companies |
| Lars Magnus Bruce | Board of Directors | 0 companies |
| John Tobhias Brandell | Board of Directors | 0 companies |
| Anders Claes Olof Kristensson | Board of Directors | 0 companies |
| Per Henrik Stefan Sallerfors | Chairman | 0 companies |
| Annika Maria Kollén | Board of Directors | 0 companies |
| Orvar Göran Ernst Gustav Groth | Chairman | 0 companies |
| Carl Anders Svensson | Board of Directors | 0 companies |